Literature DB >> 18067646

Transfusion-transmitted infections among multitransfused patients in Iran: a review.

H Rezvan1, H Abolghassemi, S Amini Kafiabad.   

Abstract

Transfusion-transmitted infections (TTI) continue to be a major challenge for Blood transfusion organizations across the world. The problem is more serious in the developing countries with lower economic means. Multitransfused patients (MTPs) in these countries are at higher risk of infection, and studies of infection in these patients can be a useful index for examining the blood safety filters in place. The present article reviews the situation in Iran, where prevalence of the major viruses of concern, namely, hepatitis B virus, hepatitis C virus (HCV) and human immunodeficiency virus, studied in these patients is reported over a 9-year period. It is demonstrated that HCV is the most prevalent TTI and remains a major health problem for these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067646     DOI: 10.1111/j.1365-3148.2007.00794.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  29 in total

Review 1.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Emerging infectious threats to the blood supply: seroepidemiological studies in iran - a review.

Authors:  Gharib Karimi; Ahmad Gharehbaghian; Mohammad Fallah Tafti; Vida Vafaiyan
Journal:  Transfus Med Hemother       Date:  2013-05-17       Impact factor: 3.747

3.  Hepatitis C Seroprevalence and Risk Factors in Adult Population of Chaharmahal and Bakhtiari Province of Iran in 2013.

Authors:  Masoumeh Moezzi; Reza Imani; Ali Karimi; Behrouz Pourheidar
Journal:  J Clin Diagn Res       Date:  2015-10-01

4.  Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study.

Authors:  Ali Asghar Pouri; Morteza Ghojazadeh; Behrouz Pourasghari; Babak Baiaz; Fatemeh Soghra Hamzavi; Mohammad Hossein Somi
Journal:  Caspian J Intern Med       Date:  2019

5.  Evaluation of new cases of HCV infection in thalassaemia patients for source of infection.

Authors:  Azita Azarkeivan; Mohsen Nasiritoosi; Sedigheh Amini Kafiabad; Mahtab Maghsudlu; Bashir Hajibeigi; Mohammad Hadizadeh
Journal:  Asian J Transfus Sci       Date:  2011-07

6.  Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin.

Authors:  Maryam Jafroodi; Ramin Asadi; Abtin Heydarzadeh; Sepiedeh Besharati
Journal:  Int J Gen Med       Date:  2011-07-13

7.  Prevalence of chronic hepatitis B infection in Iran: a review article.

Authors:  Jalal Poorolajal; Reza Majdzadeh
Journal:  J Res Med Sci       Date:  2009-07       Impact factor: 1.852

8.  Patient-to-Patient Transmission of Hepatitis C at Iranian Thalassemia Centers Shown by Genetic Characterization of Viral Strains.

Authors:  Katayoun Samimi-Rad; Freshteh Asgari; Mohsen Nasiritoosi; Abdoulreza Esteghamati; Azar Azarkeyvan; Seyedeh Masoomeh Eslami; Farhad Zamani; Lars Magnius; Seyed Moayed Alavian; Heléne Norder
Journal:  Hepat Mon       Date:  2013-01-23       Impact factor: 0.660

9.  Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran.

Authors:  Mohammad Ali Assarehzadegan; Mehri Ghafourian Boroujerdnia; Khodamorad Zandian
Journal:  Iran Red Crescent Med J       Date:  2012-08-30       Impact factor: 0.611

10.  Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study.

Authors:  Alireza Ansari-Moghaddam; Mohammad Reza Ostovaneh; Batool Sharifi Mood; Esmail Sanei-Moghaddam; Amirhossein Modabbernia; Hossein Poustchi
Journal:  Hepat Mon       Date:  2012-09-30       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.